Original Article

Rheumatology International

, Volume 25, Issue 4, pp 296-300

First online:

Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study

  • J. D. RingeAffiliated withKlinikum Leverkusen (University of Cologne) Email author 
  • , A. DorstAffiliated withKlinikum Leverkusen (University of Cologne)
  • , H. FaberAffiliated withKlinikum Leverkusen (University of Cologne)
  • , C. KipshovenAffiliated withOpfermann Arzneimittel GmbH
  • , L. C. RovatiAffiliated withRotta Research Laloratorium
  • , I. SetnikarAffiliated withRotta Research Laloratorium

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


In a three-year pilot study on 52 women with severe postmenopausal osteoporosis, treatment with etidronate followed by calcium and vitamin D (ECaD) was compared to etidronate followed by monofluorophosphate, calcium and vitamin D (EFCaD). BMD in lumbar spine, total hip and femoral neck increased significantly more with EFCaD than with ECaD. Pain-mobility score decreased significantly more with EFCaD than with ECaD (p=0.006). New vertebral fractures occurred in three patients under EFCaD (12%) and in nine under ECaD (35%), (p=0.048). Three patients under EFCaD (12%) and 15 under ECaD (58%) did not respond to therapy (p of difference=0.001). Mild or moderate adverse reactions were reported by 25 patients, with no significant difference between the two groups. The pilot study suggests that etidronate, sequentially followed by monofluorophosphate, could be a safe, effective and relatively inexpensive therapy in severe postmenopausal osteoporosis.